- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: BI-1744 | BI-1744-CL | Striverdi®
olodaterol is an approved drug (FDA (2014))
Compound class: Synthetic organic
Comment: Marketed formulations may contain olodaterol hydrochloride (PubChem CID 11711522).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: olodaterol
|No information available.|
|Summary of Clinical Use|
|Olodaterol was approved by the FDA in July 2014 as an inhalation medication for the treatment of chronic obstructive pulmonary disease (COPD). Phase II trials have also been conducted in patients with asthma (see NCT01013753).
This drug has been further assessed in clinical trials in combination with the muscarinic antagonist tiotropium bromide (also a bronchodilator).
In May 2015 the US FDA approved a fixed-dose combination of tiotropium bromide and olodaterol (Stiolto Respimat®) as 'a long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema' Drugs.com.
Click here to view a full list of associated trials registered with ClinicalTrials.gov.
|Mechanism Of Action and Pharmacodynamic Effects|
|Olodaterol is a long acting β-adrenoceptor agonist (LABA) acting on β2-ARs in the lung to cause bronchodilation which improves airway function. Olodaterol appears to have low intrinsic β1-AR action, thereby limiting cardiac side effects .|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT01013753||A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.||Phase 2 Interventional||Boehringer Ingelheim|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)